Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis

A new study shows that anti-IL-1β treatment and NLRP3 inflammasome inhibition ameliorate vascular inflammation and atherosclerosis progression by two mechanisms: a reduction in blood inflammatory leukocyte supply and a decrease in inflammatory leukocyte uptake into atherosclerotic lesions.